Haleon plc (HLN)

Haleon Invests in India to Deliver Better Everyday Health to Rural CommunitiesJune 8, 2026 5:11 AM
Business Wire £175m for first Haleon manufacturing site in Madhya Pradesh, central India Fast-growing India key to Haleon reaching one billion more consumers by 2030 India’s consumer health market to reach over £23bn by 20301 Accelerated rural distribution to access 3 million outlets Affordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as One focuses on unlocking growth, driving productivity and transforming the company’s culture. Strengthening its in-house supply chain capabilities will enable Haleon to be more resilient and able to adapt faster to consumer needs. Haleon’s investment in India reflects the clear, structural shift towards prevention and daily self-care, with the country’s consumer health market expected to reach over £23 billion by 2030. India is already one of Haleon’s largest oral health markets and this latest investment will accelerate access to its portfolio of trusted, science-backed brands including Sensodyne and parodontax across rural communities, with ambitions to reach more than three million outlets by 2030. The investment is in line with Haleon’s capital allocation priorities as outlined at the company’s Capital Markets Day in 2025. Reaching underserved communities at scale Rural India is home to around 65% of the country’s population3, spread across more than 650,000 villages4, where unmet oral health needs remain significant. Access to dental care remains highly limited in rural India, where a single dentist may serve around 250,000 people5. With as few as 1 in 7 people in rural communities6 visiting a dentist each year, many live with untreated conditions like tooth decay or sensitivity for years. With many not currently using specialist toothpaste such as Sensodyne, recommended by healthcare professionals, there is a significant opportunity to address unmet consumer needs. With many households reliant on daily wages and increasingly value conscious, Haleon will also be rolling out access to high-quality, science based oral health products made with trusted ingredients through lower-cost, small-format toothpaste packs – including its 20-rupee Sensodyne pack – across significantly more towns and villages. With sales and distribution teams now working directly into Haleon’s leadership, there is significant opportunity to transform how products reach consumers in new and innovative ways – supported by the recruitment of more than 500 people to its sales teams over the last 12 months. ‘Last-mile’ investment to build awareness and access Haleon is also investing in ‘last-mile’ capabilities, doubling frontline teams on motorbikes who are equipped with testing kits, samples and diagnostic tools and deployed to rural areas, which are often beyond the reach of traditional retail and pharmacies. Simple diagnostic tools, such as ‘chill tests’ – where consumers assess sensitivity by drinking cold water - help consumers recognise symptoms they may have had for years and connect them with science-backed treatment, often for the first time. The company is also improving access by engaging rural communities directly through education, with its network of mobile oral health literacy vans. These Sensodyne-branded vans are designed to turn local squares and marketplaces into community hubs for oral health awareness, sensitivity and gum health checks, and immediate access to products. Brian McNamara, CEO, Haleon, said: “India is a key strategic market for Haleon and an important driver of our long-term growth. This investment strengthens our local manufacturing footprint and expands our reach in one of the world’s fastest-growing consumer health markets. By increasing access to our trusted brands and building our capabilities on the ground, we are well positioned to capture the significant opportunities ahead. “We aim to expand access to better everyday health for more than 300 million additional consumers in India. This will be key to achieving our broader ambition to reach one billion more consumers globally by 2030.” The new manufacturing facility was marked by a groundbreaking ceremony and a meeting between Haleon management and the Chief Minister of Madhya Pradesh this week. It will create up to 500 jobs, strengthen local capabilities and support long-term economic development, reinforcing Haleon’s ambition to be an employer of choice in the country. It is expected to open in early 2028 with supply commencing the following year. Notes to editors Q&A Why is Haleon investing in India? India is one of Haleon’s fastest growing markets and key to achieving its ambition to reach one billion more consumers by 2030. The country’s consumer health market is forecast to reach over £23 billion by 2030, driven by rising awareness and adoption of self-care. Significant unmet health needs in rural areas, where access to care remains limited and many consumers do not yet use specialist products, create substantial headroom for growth and an opportunity to expand access to everyday health. How much is Haleon investing in India, and how will this investment be phased? Haleon is investing around £175 million of capital expenditure in a new oral health manufacturing site in Madhya Pradesh. This investment will be phased across the 2025 – 2029 period. The site is expected to open in early 2028, with supply commencing the following year, supporting the company’s long-term growth plans in India. The investment is in line with Haleon’s capital allocation priorities as outlined at the company’s Capital Markets Day in 2025. How will this investment support Haleon’s growth strategy? The investment supports Haleon’s Win as One strategy by strengthening in-house supply chain capabilities and enabling faster response to consumer needs. It also forms part of Haleon’s ‘Build for Tomorrow’ programme, which is transforming Haleon’s global supply chain to meet mid- to long-term needs, including through investments in key growth markets such as India and China. Will the new manufacturing site support exports to other markets? The new site focuses on meeting growing demand within India, one of our fastest-growing markets, while also serving other parts of Asia. The site strengthens local manufacturing capabilities and supply chain resilience, while forming part of our broader global supply chain transformation. How does this investment strengthen Haleon’s presence in India? We actively invest in markets where we see opportunities to drive innovation and create value. This investment strengthens Haleon’s capabilities in India by expanding local manufacturing and building a more localised, resilient supply network closer to consumers. It enhances agility to meet growing demand - particularly in underserved and rural communities - while supporting the company’s broader efforts to optimise and transform its global supply chain. How many people does Haleon employ in India, and will this investment create jobs? Haleon already employs a significant workforce across India. The new manufacturing site will create 500 jobs and strengthen local capabilities. In addition, the company has recruited more than 500 people into its sales teams over the last 12 months to support expanded distribution. How does this announcement build on Haleon’s existing presence in India? Since becoming a standalone company in 2022, Haleon has redefined its presence in India - building its own end-to-end dedicated salesforce and distribution network. This investment builds on that foundation, strengthening route-to-market and accelerating rural outreach to reach more underserved communities. Why have you selected Madhya Pradesh as the location for the new site? Madhya Pradesh is well-positioned in the centre of the country with the site selected due to its close proximity to infrastructure, higher education, logistics, talent and incentives. Where does India sit within Haleon’s global operating model? Haleon’s new operating model – announced early this year - established India Subcontinent as a distinct Operating Unit, reporting directly into the Chief Executive, reflecting the scale and growth potential of the market and reinforcing the strategic importance of this investment. About Haleon Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are trusted by more than one billion consumers and are recommended by health professionals around the world. For more information, please visit www.haleon.com 1 Source: IQVIA Market Prognosis (consumer health), India, 2024–2030 estimates. 2 £175m reflects gross Investment at 1 Pound = INR 115 3 Press Release Page | Press Information Bureau 4 Press Release: Press Information Bureau 5 (PDF) An Overview of Oral Health in India: Current Scenario and Challenges 6 https://pmc.ncbi.nlm.nih.gov/articles/PMC12220351/   View source version on businesswire.com: https://www.businesswire.com/news/home/20260608753094/en/ Philippa Keir - philippa.l.keir@haleon.com - +447969271455
Victoria Durman - victoria.a.durman@haleon.com - +447894505730 Original: Haleon Invests in India to Deliver Better Everyday Health to Rural Communities

Haleon Issues Voluntary Nationwide Recall of Gas-X Extra Strength Softgels 125mg, 120 ct. and 72 ct.June 4, 2026 2:32 PM
Business Wire Haleon (NYSE: HLN) is voluntarily recalling four lots of Gas-X Extra Strength Softgels 125mg, 120 ct. and 72 ct. distributed on or about April 13, 2026 to the consumer level. The lots are being recalled due to potential contamination with a diluted propylene glycol-based coolant from a machine leakage during the packaging process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604056780/en/Gas-X Extra Strength Softgels (120 ct.) Front of Carton There is a potential that ingestion of the Softgels contaminated with the diluted propylene glycol-based coolant may result in adverse events such as nausea, vomiting, abdominal pain and diarrhea. To date, Haleon has not received any reports of adverse events related to this recall. Gas-X Extra Strength Softgels are indicated to quickly break up gas bubbles in the digestive tract and relieve pressure, bloating, and discomfort. Gas-X Extra Strength Softgels are uniquely identified as a green capsule and found in packaging with a green band. Only the lots in the table below are impacted. No other lots of Gas-X Extra Strength, Gas-X Ultra, Gas-X Maximum and Gas-X Ultimate are impacted by this recall. Product UPC Lot Number Expiry Date Dates of Distribution Gas-X Extra Strength Softgels (120 ct.) 300674350419 TL8K YH9X YH9Y 30 Nov 2028 30 Nov 2028 30 Nov 2028 13 Apr 2026 – 05 May 2026 Gas-X Extra Strength Softgels (72 ct.) 300439005721 X78N 30 Nov 2028 05 May 2026 – 14 May 2026 This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). Haleon is notifying its distributors and customers by letter, email, and phone notification, and is arranging for the return of all recalled products. Consumers who have purchased Gas-X Extra Strength Softgels on or after April 13, 2026, should review the lot number. If the lot number matches those impacted by this recall, stop taking the product immediately and contact the Haleon Consumer Relations team at +1-800-245-1040 (Monday through Friday 8 a.m. to 6 p.m. ET), or via mystory.us@haleon.com or https://haleon.help/en-us/contact-form to arrange for return of the product and request reimbursement. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. They should also report any adverse events to our Consumer Relations Team at +1-800-245-1040 (Monday through Friday 8 a.m. to 6 p.m. ET) or via mystory.us@haleon.com or https://haleon.help/en-us/contact-form. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: www.fda.gov/medwatch/report.htm. Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178. Consumer safety and product quality are our utmost priorities at Haleon. The root cause of the contamination has been identified and repaired. Corrective and preventative actions have been implemented to prevent future recurrence. About Haleon Haleon (LSE/NYSE: HLN) is a globally leading consumer company that is solely focused on better everyday health. Haleon's product portfolio spans three major categories - Oral Health, Over-the-Counter (OTC), and Wellness. Its long-standing brands - such as Advil, Centrum, Parodontax, Sensodyne, Theraflu, and TUMS - are built on trusted science, innovation and deep human understanding. For more information on Haleon and its brands, please visit www.haleon.com or contact USMediaRelations@haleon.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260604056780/en/ Media Contact:

TUMS Kicks Off the "TUMS Food Match Cup," a Celebration of Global Soccer Fandom and Food Love Through Bold Flavor MashupsJune 3, 2026 9:42 AM
PR Newswire (US) New campaign features global-inspired recipes, a multi-city food truck tour, creator collaborations, a sweepstakes and more, inspired by the summer's biggest soccer tournamentWARREN, N.J., June 3, 2026 /PRNewswire/ -- As soccer fans around the world gather to cheer on their favorite teams this summer, TUMS is bringing fans together over another shared passion: food. An extension of Haleon's partnership with U.S. Soccer, TUMS has announced the launch of the "TUMS Food Match Cup," a first-of-its-kind campaign inspired by the global flavors, traditions and team passions that make soccer's biggest tournament season unforgettable. From bold culinary mashups and creator collaborations to immersive fan experiences and daily sweepstakes, the TUMS Food Match Cup celebrates the intersection of soccer fandom, food culture and fast-acting heartburn relief — helping fans stay focused on the action, not their symptoms. "Soccer's biggest moments bring fans from around the world together, and food is often at the center of those celebrations — whether it's spicy street tacos, grilled favorites or comforting classics shared while cheering on your team," said Patricia Melo, Brand Director for TUMS. "With the TUMS Food Match Cup, we wanted to celebrate that sense of global unity through original recipe mashups inspired by countries competing on the pitch, combining iconic flavors and dishes from around the world into unexpected, crave-worthy creations, all paired with trusted heartburn relief that helps fans stay focused on the celebration."Featured dishes include:The Plantain Dog, a sweet-and-savory fusion inspired by flavors from the USA and ParaguayKimchi Carnitas Tacos, blending Korean and Mexican culinary traditionsRaclette Poutine, combining Swiss alpine comfort food with a Canadian classicThroughout the tournament, fans can visit TUMSFoodMatchCup.com to spin the daily wheel for a chance to unlock a new recipe mashup inspired by competing countries and their signature cuisines, along with a recommended TUMS product pairing. Fans can also enter daily for a chance to win prizes, including U.S. Soccer merchandise, special savings offers from TUMS and the grand prize: a $200 Ticketmaster e-gift card that can be used toward U.S. Soccer tickets.The campaign will also be amplified through additional creator partnerships, including a partnership with chef, creator and cookbook author Joshua Weissman."To me, food and soccer have this incredible ability to bring people together and spark a sense of connection and creativity," said Joshua Weissman. "Working with TUMS on the Food Match Cup gave me the chance to help celebrate unexpected flavors and culinary traditions in a way that encompasses the energy and excitement that fans are feeling all summer long."TUMS is also bringing the campaign directly to fans through the Food Match Cup Food Truck Tour, a multi-city experience designed to celebrate the excitement of match day through globally inspired flavors and interactive fan engagement. The tour will stop in Los Angeles, Houston, Kansas City, Dallas and New York City, making 14 stops at retail locations, including Walmart and Kroger, as well as the Gameday Goal Zone Pre-Match Hospitality event at MetLife Stadium.Visitors can sample tournament-inspired dishes from the TUMS food truck, capture memories through interactive photo opportunities, enjoy giveaways and receive TUMS samples and products — all designed to help ensure heartburn doesn't interrupt the excitement of game day.Fans can follow along throughout the tournament to discover new recipe mashups, enter the sweepstakes and find upcoming tour stops at TUMSFoodMatchCup.com and on @TUMSOfficial across Instagram and TikTok.About TUMS
TUMS is the #1 recommended antacid brand by doctors, pharmacists and OBGYNs. As America's #1 antacid brand, TUMS offers a wide variety of flavors and formats with something for everyone. TUMS Chewy Bites provide tasty, effective multi-symptom relief from heartburn, sour stomach, acid indigestion and upset stomach so you can savor the moment. TUMS Gummy Bites go to work in seconds* for occasional heartburn relief and feature a soft, easy-to-chew format with multi-benefit relief from occasional sour stomach, acid indigestion and upset stomach.*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.About Haleon
Haleon (LSE/NYSE: HLN) is a globally leading consumer company that is solely focused on better everyday health. Haleon's product portfolio spans three major categories - Oral Health, Over-the-Counter (OTC), and Wellness. Its long-standing brands - such as Advil, Centrum, Parodontax, Sensodyne, Theraflu, and TUMS - are built on trusted science, innovation and deep human understanding. For more information on Haleon and its brands, please visit www.haleon.com or contact USMediaRelations@haleon.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/tums-kicks-off-the-tums-food-match-cup-a-celebration-of-global-soccer-fandom-and-food-love-through-bold-flavor-mashups-302790131.htmlSOURCE TUMS Original: TUMS Kicks Off the "TUMS Food Match Cup," a Celebration of Global Soccer Fandom and Food Love Through Bold Flavor Mashups

Haleon Appoints Richard Manso as US Chief Marketing Officer to Advance Data-driven, Consumer-centric Marketing in Delivering Better Everyday HealthApril 27, 2026 10:00 AM
Business Wire
Today Haleon (NYSE: HLN), the consumer company that is solely focused on better everyday health, announced the appointment of Richard Manso as US Chief Marketing Officer, effective April 27, 2026. In this role, Manso will partner closely with CEO, US & President, North America Nathalie Gerschtein and the US leadership team to accelerate Haleon’s evolution into a more agile, consumer-centric organization.


Manso will lead Haleon’s integrated US marketing organization, advancing how the company connects with consumers in the moments where health decisions actually happen. He will work across categories and global teams to integrate data, technology and human insight, strengthening Haleon’s ability to deliver more personalized, transparent and relevant health experiences.


His appointment comes at a time of significant transformation in consumer health, as individuals take a more active, self-directed role in managing their well-being and increasingly expect seamless, personalized, and on-demand experiences. In this environment, marketing is emerging as a critical driver of trust - shaping how companies show up across every touchpoint in everyday life.


At Haleon, Manso will focus on strengthening modern marketing capabilities across the US business—driving growth within and across categories, and advancing priority areas including Medicare Advantage OTC, GLP-1, and emerging platforms such as Women’s and Pediatric Health. His role will also support Haleon’s broader ambition to build a more connected, insight-led marketing ecosystem that reflects how consumers engage with health today.


“Consumers are taking a more active role in managing their health—and that’s raising expectations for the brands they trust,” said Nathalie Gerschtein, US CEO and President, North America, Haleon. “At Haleon, we see an opportunity to rethink how we engage—making it more personal, transparent, and connected to the moments where health decisions happen. Richard brings a forward-looking perspective at the intersection of marketing, data and technology that will help us continue to evolve and deliver better everyday health with humanity.”


Manso brings experience across marketing, technology and digital transformation, most recently serving in senior leadership roles at Google, where he led large-scale B2B marketing programs and helped drive adoption of data and AI-enabled marketing solutions. His background also includes leadership roles spanning consumer brands and digital strategy.


Richard Manso commented: “I’m excited to join Haleon at such a pivotal moment for both the company and the consumer health category. As people take greater ownership of their health, there’s a real opportunity to rethink how brands show up, not just as products, but as trusted partners in everyday life. I’m looking forward to working with Nathalie and the team to bring together data, technology, and creativity to build more meaningful connections with consumers and drive the next phase of growth.”


Manso will report directly to Nathalie and serve as a member of the US Leadership Team.


About Haleon

Haleon (LSE/NYSE: HLN) is a globally leading consumer company that is solely focused on better everyday health. Haleon's product portfolio spans three major categories - Oral Health, Over-the-Counter (OTC), and Wellness. Its long-standing brands - such as Advil, Centrum, Parodontax, Sensodyne, Theraflu, and TUMS - are built on trusted science, innovation and deep human understanding. For more information on Haleon and its brands, please visit www.haleon.com or contact USMediaRelations@haleon.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427877997/en/
USMediaRelations@haleon.com


Original: Haleon Appoints Richard Manso as US Chief Marketing Officer to Advance Data-driven, Consumer-centric Marketing in Delivering Better Everyday Health

Haleon baut vor dem Hintergrund des gestiegenen Fokus der Verbraucher auf eine bessere Gesundheit im Alltag sein Engagement in China ausMarch 11, 2026 8:22 PM
Business Wire

Investition in Höhe von 65 Millionen Pfund in eine neue Produktionsanlage für Mundgesundheitsprodukte in Shanghai, um das Wachstum auf dem weltweit größten Markt für Zahnfleischgesundheit zu unterstützen




Haleon möchte die Marke für Zahnfleischgesundheit parodontax bis Ende 2027 auf 30 chinesische Städte ausweiten – darunter auch die am schnellsten wachsenden Städte – und anspruchsvolle Käufer sowohl im stationären Handel als auch online ansprechen




Ein speziell entwickelter Geschmack, ein schaumigeres Gefühl und eine hochwertige Verpackung sollen lokale Verbraucher ansprechen



Haleon, ein Konsumgüterunternehmen, dessen alleiniger Fokus auf einer besseren Gesundheit im Alltag liegt, investiert 65 Millionen Pfund in eine neue, hochmoderne Produktionsanlage für Mundpflegeprodukte in Shanghai. Die Anlage wird die Expansion seines die globalen Marken Sensodyne und parodontax umfassenden Mundpflegeportfolios in Chinas schnell wachsenden Tier-2- und Tier-3-Städten unterstützen, wo steigende Einkommen, ein wachsendes Bewusstsein für Gesundheit im Alltag und der Trend zu vertrauenswürdigen Markenprodukten das Verbraucherverhalten verändern.

Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/home/20260311348281/de/parodontax, Haleon's clinically proven gum health brand, is expanding across China
Als Teil dieses Wandels integrieren immer mehr Verbraucher präventive Mundpflege in ihre täglichen Selbstpflegeroutinen, und die Nachfrage nach hochwertigen, wissenschaftlich fundierten Lösungen nimmt rasant zu. Diese Investition stärkt die lokale Produktion von Haleon und positioniert das Unternehmen für langfristiges Wachstum in einem seiner dynamischsten Märkte.


Der chinesische Markt für Zahnfleischgesundheit ist der größte weltweit und hat ein Volumen von rund 860 Millionen Pfund. Über 70 % der Erwachsenen in China haben in irgendeiner Form Zahnfleischprobleme, und das Bewusstsein für Symptome wie Blutungen, Rötungen und Empfindlichkeit nimmt zu. Dies bietet erhebliche Marktchancen für klinisch erprobte Produkte für die Zahnfleischgesundheit.


parodontax, die am schnellsten wachsende Marke für Mundgesundheit von Haleon, ist die erste Zahnpasta auf dem chinesischen Markt, die klinisch erwiesenermaßen die Ursache für Zahnfleischbluten bekämpft, indem sie hartnäckigen Zahnbelag, eine der Hauptursachen für Zahnfleischerkrankungen, entfernt. Allerdings unterscheidet sich ihr charakteristisches Geschmacksprofil, das durch den Hauptwirkstoff Natriumbikarbonat bedingt ist, von vielen lokal erhältlichen Zahnpasten, die in der Regel einen süßeren oder blumigeren Geschmack haben.


Um sicherzustellen, dass die chinesischen Verbraucher das Produkt positiv aufnehmen, hat das globale F&E-Team von Haleon eng mit lokalen Sensorikwissenschaftlern zusammengearbeitet, um den Geschmack anzupassen und dabei die Wirksamkeit der globalen Rezeptur durch süßere, aromatischere Noten und ein schaumigeres Putzerlebnis zu optimieren, ohne die klinische Leistungsfähigkeit zu beeinträchtigen. Durch die hochwertige Verpackung werden die therapeutischen, klinisch nachgewiesenen Eigenschaften in einem immer anspruchsvolleren Markt für Mundpflegeprodukte zusätzlich hervorgehoben.


Haleon verfolgt zudem eine Multi-Channel-Vertriebsstrategie, um den Zugang zu parodontax in ganz China auszubauen. Neben der schnell zunehmenden Präsenz auf E-Commerce-Plattformen wie Douyin will das Unternehmen den Vertrieb von parodontax bis Ende 2027 auf 30 Städte ausweiten und so mit der Marke mehr als 250 Millionen Menschen erreichen. In diesen Städten lebt eine zunehmend wohlhabende Mittelschicht mit steigendem verfügbaren Einkommen und Interesse an renommierten internationalen Marken. Große Club-Einzelhändler expandieren schnell, und Haleon ist auch weiterhin sehr präsent in stationären und Online-Apotheken, unterstützt durch ein Netzwerk von Zahnärzten, die die Produkte regelmäßig empfehlen.


Brian McNamara, Chief Executive von Haleon, erklärte: „China hat für Haleon strategisch Priorität. Diese Investition, die auf unseren bewährten F&E-Kompetenzen und unserem starken lokalen Team aufbaut, spiegelt unser langfristiges Engagement wider, das Beste aus unserer globalen Forschung und Innovation einzubringen, um die Gesundheit und das Wohlbefinden der chinesischen Verbraucher zu verbessern.“


„Indem wir unsere Forschungskompetenz von Weltklasse mit fundierten lokalen Kenntnissen und Fertigungs- und F&E-Kapazitäten vor Ort kombinieren, können wir qualitativ hochwertige, auf wissenschaftlichen Erkenntnissen basierende Produkte anbieten, die die Gesundheit der Menschen in China im Alltag verbessern.“


Die neue Anlage für Mundgesundheitsprodukte wird in Shanghais Lingang New Area, einem schnell wachsenden Industriezentrum, entstehen. Indem Haleon die Lieferkapazitäten für China intern bereitstellt, möchte das Unternehmen schneller auf sich ändernde Verbraucherpräferenzen reagieren können und Innovationen in einer schnell wachsenden Kategorie beschleunigen, was sein Ziel unterstützt, bis 2030 eine Milliarde weitere Verbraucher zu erreichen und gleichzeitig durch eine agilere und effizientere Lieferkette in den nächsten fünf Jahren Bruttoproduktivitätseinsparungen in Höhe von 800 Millionen Pfund zu erzielen.


Im Juni 2025 hat Haleon außerdem die vollständige Übernahme seines Joint Ventures TSKF mit einer Investition von rund 700 Millionen Pfund abgeschlossen, wodurch das Unternehmen die direkte Kontrolle über sein OTC-Geschäft in China übernommen hat. Zusammen verdeutlichen diese Investitionen das langfristige Vertrauen von Haleon in das Wachstum des chinesischen Marktes für Verbrauchergesundheitsprodukte.


Über Haleon


Haleon (LSE/NYSE: HLN) ist ein Konsumgüterunternehmen, dessen alleiniger Fokus auf einer besseren Gesundheit im Alltag liegt. Unsere Mitarbeiter, unsere Marken, unsere Forschung, unsere Investitionen und unsere Innovationen dienen alle dem Ziel, die Gesundheit der Verbraucher im Alltag zu verbessern. Unser Produktportfolio umfasst sechs Hauptkategorien: Mundgesundheit, Vitamine, Mineralien und Nahrungsergänzungsmittel (Vitamins, Minerals and Supplements, VMS), Schmerzlinderung, Atemwegsgesundheit, Verdauungsgesundheit sowie therapeutische Haupflege und Sonstiges. Unsere führenden Marken, darunter Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu und Voltaren, genießen das Vertrauen von über einer Milliarde Verbrauchern und werden von Gesundheitsexperten weltweit empfohlen.


Weitere Informationen erhalten Sie unter www.haleon.com.


Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260311348281/de/
Haleon Medienkontakt:

Gemma Thomas

E-Mail: gemma.x.thomas@haleon.com

Mobil: +44 (0) 7985 175048


Original: Haleon baut vor dem Hintergrund des gestiegenen Fokus der Verbraucher auf eine bessere Gesundheit im Alltag sein Engagement in China aus

Haleon renforce son engagement envers la Chine alors que les consommateurs se concentrent sur une meilleure santé au quotidienMarch 11, 2026 8:04 PM
Business Wire

Investissement de 65 millions de livres sterling dans une nouvelle usine de fabrication de produits d'hygiène bucco-dentaire à Shanghai pour soutenir la croissance du plus grand marché mondial des produits de santé gingivale




Haleon vise à étendre la marque de produits de santé gingivale parodontax à 30 villes chinoises d'ici la fin 2027, y compris les villes à la croissance la plus rapide, afin d'atteindre les consommateurs ambitieux en magasin et en ligne




Saveur personnalisée, sensation plus mousseuse et emballage haut de gamme pour séduire les consommateurs locaux



Haleon, la société de consommation qui se concentre exclusivement sur l'amélioration de la santé au quotidien, investit 65 millions de livres sterling dans un nouveau site de fabrication de produits d'hygiène bucco-dentaire à la pointe de la technologie à Shanghai. Cette installation permettra d'étendre son portefeuille de produits d'hygiène bucco-dentaire, qui comprend les marques mondiales Sensodyne et parodontax, aux villes chinoises de deuxième et troisième rangs en pleine croissance, où l'augmentation des revenus, la sensibilisation croissante à la santé au quotidien et le passage à des produits de marque fiables sont en train de remodeler le comportement des consommateurs.

Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20260311796414/fr/parodontax, Haleon's clinically proven gum health brand, is expanding across China
Dans le cadre de cette évolution, de plus en plus de consommateurs intègrent les soins bucco-dentaires préventifs dans leur routine quotidienne, et la demande de solutions haut de gamme et scientifiquement prouvées s'accélère à un rythme rapide. Cet investissement renforce l'implantation industrielle de Haleon en Chine et positionne l'entreprise de manière à tirer parti de la croissance à long terme de l'un de ses marchés les plus dynamiques.


Le marché chinois des produits de santé gingivale est le plus important au monde, avec une valeur estimée à environ 860 millions de livres sterling. Avec plus de 70 % des adultes chinois souffrant d'un problème gingival et une prise de conscience croissante des symptômes tels que les saignements, les rougeurs et la sensibilité, cela représente des opportunités de marché importantes pour les produits de santé gingivale cliniquement prouvés.


parodontax, la marque de santé bucco-dentaire de Haleon qui connaît la plus forte croissance, est le premier dentifrice en Chine cliniquement prouvé pour traiter la cause profonde des saignements gingivaux en éliminant la plaque dentaire tenace, qui est l'une des principales causes des maladies gingivales. Cependant, son profil sensoriel distinctif, dû à son ingrédient actif clé, le bicarbonate de sodium, diffère de celui de nombreux dentifrices locaux, qui ont tendance à avoir des profils aromatiques plus sucrés ou plus floraux.


Afin de s'assurer que le produit trouve un écho auprès des consommateurs chinois, l'équipe mondiale de R&D de Haleon a travaillé en étroite collaboration avec des scientifiques locaux spécialisés dans le domaine sensoriel pour adapter l'arôme, en équilibrant l'efficacité de la formulation mondiale avec des notes plus sucrées et plus parfumées et une expérience de brossage plus mousseuse, tout en conservant ses performances cliniques. Son emballage haut de gamme met davantage en valeur ses bienfaits thérapeutiques cliniquement prouvés dans un rayon de soins bucco-dentaires de plus en plus sophistiqué.


Haleon adopte également une stratégie de vente au détail multicanal afin d'élargir l'accès à parodontax dans toute la Chine. Qui plus est, la société a une présence en pleine expansion sur les plateformes de commerce électronique telles que Douyin. Elle vise à étendre la distribution de parodontax à 30 villes d'ici la fin 2027, mettant ainsi la marque à la portée de plus de 250 millions de personnes. Ces villes abritent une classe moyenne en pleine expansion, dont le revenu disponible augmente et qui recherche des marques internationales de confiance. Les grandes surfaces de vente au détail connaissent une expansion rapide, tandis que Haleon maintient également une forte présence dans les pharmacies de détail, tant en magasin qu'en ligne, grâce au soutien d'un réseau de professionnels dentaires qui recommandent régulièrement ses produits.


Brian McNamara, directeur général de Haleon, a indiqué : « La Chine est une priorité stratégique pour Haleon. S'appuyant sur nos capacités de R&D établies et notre solide équipe locale, cet investissement reflète notre engagement à long terme à mettre le meilleur de notre science et de notre innovation mondiales au service de l'amélioration de la santé et du bien-être des consommateurs chinois.


« En combinant notre expertise de recherche de classe mondiale avec une connaissance approfondie du marché local et des capacités de fabrication et de R&D sur le terrain, nous proposons des produits de haute qualité, fondés sur la science, qui améliorent la santé quotidienne en Chine. »


La nouvelle usine de produits bucco-dentaires sera située dans la nouvelle zone de Lingang à Shanghai, un pôle industriel en pleine expansion. En internalisant sa capacité d'approvisionnement pour la Chine, Haleon vise à répondre plus rapidement à l'évolution des préférences des consommateurs et à accélérer l'innovation dans un secteur en pleine croissance, soutenant ainsi son ambition d'atteindre un milliard de consommateurs supplémentaires d'ici 2030, tout en générant 800 millions de livres sterling d'économies brutes de productivité au cours des cinq prochaines années grâce à une chaîne d'approvisionnement plus agile et plus efficace.


En juin 2025, Haleon a également finalisé l'acquisition complète de sa coentreprise TSKF avec un investissement d'environ 700 millions de livres sterling, prenant ainsi le contrôle direct de son activité de vente libre en Chine. Ensemble, ces investissements soulignent la confiance à long terme de Haleon dans la croissance du marché chinois des soins de santé grand public.


À propos de Haleon


Haleon (LSE/NYSE : HLN) est une société grand public qui se consacre exclusivement à l'amélioration de la santé au quotidien. Notre personnel, nos marques, nos recherches, nos investissements et nos innovations visent à améliorer la santé quotidienne des consommateurs. Notre portefeuille de produits couvre six grandes catégories : santé bucco-dentaire, vitamines, minéraux et compléments alimentaires (VMS), soulagement de la douleur, santé respiratoire, santé digestive, santé thérapeutique de la peau et autres. Nos marques de premier plan, telles que Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu et Voltaren, bénéficient de la confiance de plus d'un milliard de consommateurs et sont recommandées par les professionnels de santé du monde entier.


Pour plus d'informations, veuillez consulter le site www.haleon.com.


Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260311796414/fr/
Contact avec les médias :

Gemma Thomas

E-mail : gemma.x.thomas@haleon.com

Mobile : +44 (0) 7985 175048


Original: Haleon renforce son engagement envers la Chine alors que les consommateurs se concentrent sur une meilleure santé au quotidien

????????????????????????????????????????????March 11, 2026 6:59 PM
Business Wire

???????????????????????????????????????6,500???????




??????????????????????????2027???????30???????????????????????????????????????




????????????????????????????????????????????


(???????) --
????????????????????????????????????·???????????????????????6,500?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

?????????????????????????????????????????????:https://www.businesswire.com/news/home/20260311855500/ja/parodontax, Haleon's clinically proven gum health brand, is expanding across China
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????


???????????????????????????8?6,000???????????????????70%????????????????????????????????????????????????????????????????????????????????????????


???????????????????????????????????????????????????????????(????)???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????


?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????


????????????????????????????????????????????????????????????????????(Douyin)????EC????????????????2027?????30??????????2?5,000????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????


?????????????????????·?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????


???????????????????????????????????????????????????????????????????????????????????????


???????????????????????????·??????????????????????????????????????????????????????????????????????????????????????????????????????????????????2030???????10????????????????????????????5???8?????????????????????????????


?????????2025?6???7?????????????TSKF??????????????????????(OTC)?????????????????????????????????????????????????????????????????


?????????


?????(LSE/NYSE: HLN)??????????????????????????????????????????????????????????????????????????????????????????????????????????????·????·??????(VMS)??????????????????????????????????6???????????????????????????????????????????????????????????????????????????????????????????????10?????????????????????????????????????


????www.haleon.com????????


??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

businesswire.com????????????:https://www.businesswire.com/news/home/20260311855500/ja/
Haleon media contact:

Gemma Thomas

Email: gemma.x.thomas@haleon.com

Mobile: +44 (0) 7985 175048


Original: ????????????????????????????????????????????

Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday HealthMarch 11, 2026 2:40 PM
Business Wire

£65m investment in new oral health manufacturing plant in Shanghai to support growth in the world’s largest gum health market




Haleon aiming to extend gum health brand parodontax to 30 Chinese cities by end of 2027 - including its fastest growing cities – reaching aspirational shoppers in-store and online




Custom designed taste, foamier sensation and premium packaging to appeal to local consumers



Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311389622/en/parodontax, Haleon's clinically proven gum health brand, is expanding across China
As part of this shift, more consumers are embedding preventative oral care into their daily self-care routines, and demand for premium, science-backed solutions is accelerating at a rapid pace. This investment strengthens Haleon’s local manufacturing footprint and positions the business to capture long-term growth in one of its most dynamic markets.


China’s gum health market is the largest in the world, valued at approximately £860 million. With over 70% of adults in China experiencing some form of gum issue and rising awareness of symptoms such as bleeding, redness and tenderness, this presents significant market opportunities for clinically proven gum health products.


parodontax — Haleon’s fastest-growing oral health brand — is the first toothpaste in China clinically proven to target the root cause of bleeding gums by breaking down stubborn plaque, which is a leading cause of gum disease. However, its distinctive sensory profile, driven by its key active ingredient, sodium bicarbonate, differs from many local toothpastes, which tend to have sweeter or more floral flavour profiles.


To ensure the product resonates with Chinese consumers, Haleon’s global R&D team worked closely with local sensory scientists to adapt the flavour — balancing the efficacy of the global formulation with sweeter, more fragrant notes and a foamier brushing experience, while maintaining its clinical performance. Premium packaging further highlights its therapeutic, clinically proven benefits in an increasingly sophisticated oral care aisle.


Haleon is also adopting a multi-channel retail strategy to expand access to parodontax across China. In addition to its rapidly growing presence across e-commerce platforms like Douyin, the company aims to extend parodontax distribution to 30 cities by the end of 2027, bringing the brand within reach of more than 250 million people. These cities are home to a rising middle class with increasing disposable income and appetite for trusted international brands. Large-format club retailers are expanding quickly, while Haleon also maintains a strong presence in retail pharmacies — both in-store and online — supported by a network of dental professionals who regularly recommend its products.


Brian McNamara, Chief Executive of Haleon, said: “China is a strategic priority for Haleon. Building on our established R&D capabilities and strong local team, this investment reflects our long-term commitment to bringing the very best of our global science and innovation to improve the health and wellbeing of Chinese consumers.


“By combining our world-class research expertise with deep local insights and on-the-ground manufacturing and R&D capabilities, we are delivering high-quality, science-backed products that improve everyday health in China.”


The new oral health facility will be located in Shanghai’s Lingang New Area, a fast-growing industrial hub. By bringing supply capacity for China in-house, Haleon aims to respond more quickly to evolving consumer preferences and accelerate innovation in a rapidly growing category — supporting its ambition to reach one billion more consumers by 2030, while generating £800m in gross productivity savings over the next five years through a more agile and efficient supply chain.


In June 2025, Haleon also completed the full acquisition of its TSKF joint venture with an investment of approximately £700 million, taking direct control of its Over-the-Counter business in China. Together, these investments underline Haleon’s long-term confidence in the growth of China’s consumer healthcare market.


About Haleon


Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are trusted by more than one billion consumers and are recommended by health professionals around the world.


For more information, please visit www.haleon.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311389622/en/
Haleon media contact:

Gemma Thomas

Email: gemma.x.thomas@haleon.com

Mobile: +44 (0) 7985 175048


Original: Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health

Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday HealthMarch 11, 2026 5:00 AM
Business Wire

£65m investment in new oral health manufacturing plant in Shanghai to support growth in the world’s largest gum health market




Haleon aiming to extend gum health brand parodontax to 30 Chinese cities by end of 2027 - including its fastest growing cities – reaching aspirational shoppers in-store and online




Custom designed taste, foamier sensation and premium packaging to appeal to local consumers



Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311389622/en/parodontax, Haleon's clinically proven gum health brand, is expanding across China
As part of this shift, more consumers are embedding preventative oral care into their daily self-care routines, and demand for premium, science-backed solutions is accelerating at a rapid pace. This investment strengthens Haleon’s local manufacturing footprint and positions the business to capture long-term growth in one of its most dynamic markets.


China’s gum health market is the largest in the world, valued at approximately £860 million. With over 70% of adults in China experiencing some form of gum issue and rising awareness of symptoms such as bleeding, redness and tenderness, this presents significant market opportunities for clinically proven gum health products.


parodontax — Haleon’s fastest-growing oral health brand — is the first toothpaste in China clinically proven to target the root cause of bleeding gums by breaking down stubborn plaque, which is a leading cause of gum disease. However, its distinctive sensory profile, driven by its key active ingredient, sodium bicarbonate, differs from many local toothpastes, which tend to have sweeter or more floral flavour profiles.


To ensure the product resonates with Chinese consumers, Haleon’s global R&D team worked closely with local sensory scientists to adapt the flavour — balancing the efficacy of the global formulation with sweeter, more fragrant notes and a foamier brushing experience, while maintaining its clinical performance. Premium packaging further highlights its therapeutic, clinically proven benefits in an increasingly sophisticated oral care aisle.


Haleon is also adopting a multi-channel retail strategy to expand access to parodontax across China. In addition to its rapidly growing presence across e-commerce platforms like Douyin, the company aims to extend parodontax distribution to 30 cities by the end of 2027, bringing the brand within reach of more than 250 million people. These cities are home to a rising middle class with increasing disposable income and appetite for trusted international brands. Large-format club retailers are expanding quickly, while Haleon also maintains a strong presence in retail pharmacies — both in-store and online — supported by a network of dental professionals who regularly recommend its products.


Brian McNamara, Chief Executive of Haleon, said: “China is a strategic priority for Haleon. Building on our established R&D capabilities and strong local team, this investment reflects our long-term commitment to bringing the very best of our global science and innovation to improve the health and wellbeing of Chinese consumers.


“By combining our world-class research expertise with deep local insights and on-the-ground manufacturing and R&D capabilities, we are delivering high-quality, science-backed products that improve everyday health in China.”


The new oral health facility will be located in Shanghai’s Lingang New Area, a fast-growing industrial hub. By bringing supply capacity for China in-house, Haleon aims to respond more quickly to evolving consumer preferences and accelerate innovation in a rapidly growing category — supporting its ambition to reach one billion more consumers by 2030, while generating £800m in gross productivity savings over the next five years through a more agile and efficient supply chain.


In June 2025, Haleon also completed the full acquisition of its TSKF joint venture with an investment of approximately £700 million, taking direct control of its Over-the-Counter business in China. Together, these investments underline Haleon’s long-term confidence in the growth of China’s consumer healthcare market.


About Haleon


Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are trusted by more than one billion consumers and are recommended by health professionals around the world.


For more information, please visit www.haleon.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311389622/en/
Haleon media contact:

Gemma Thomas

Email: gemma.x.thomas@haleon.com

Mobile: +44 (0) 7985 175048


Original: Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health

Study in Nature Medicine Finds Taking Centrum Silver Daily May Slow Biological AgingMarch 9, 2026 1:00 PM
Business Wire
An analysis of the COSMOS randomized trial provides early evidence that taking a daily multivitamin may help support healthy aging at the cellular level


A new ancillary study published in Nature Medicine shows that Centrum Silver may slow biological aging markers.


The findings come from an analysis of data from a randomized clinical trial, the COcoa Supplement and Multivitamin Outcomes Study (COSMOS), designed to evaluate how daily multivitamin use may influence biological aging over time. Biological aging refers to how well the body is functioning at a cellular level and may add important information about health span than chronological age alone. Led by researchers at Mass General Brigham and Augusta University, this study looked at five DNA-based epigenetic clocks to see how a daily multivitamin might influence healthy aging in healthy older adults.


COSMOS represents the first and only reported, large-scale randomized controlled trial that examined the effect of a daily multivitamin and cocoa extract supplementation on biological aging using epigenetic clocks, which assess tiny changes in DNA that shift naturally as people age and can be used to estimate aging and age-related risk patterns.


Key Findings from the COSMOS Ancillary Study



Compared to the placebo-only group, people in the multivitamin group had slowing in all five epigenetic clocks, including statistically significant slowing seen in the two clocks that are predictive of mortality. Study authors state that the changes equated to about four months less biological aging over the course of two years.



Effects were stronger among participants who had accelerated biological aging at baseline, suggesting that individuals with higher biological age may derive greater benefit.



Authors note further research is needed to determine how changes in biological aging measures relate to long-term health outcomes.



Why This Matters



This COSMOS ancillary study offers new evidence that taking a daily multivitamin (Centrum Silver, which was used in the study) may help slow biological aging in older adults. This is the first reported evidence from a large-scale and long-term randomized controlled trial that a daily multivitamin is a safe, readily accessible, and low-cost intervention that may slow epigenetic aging.



Ancillary Study Highlights



Participants: Nearly 1,000 older men aged ≥60 years and women aged ≥65 years, followed for two years.



Intervention: The study participants were randomized to take a daily multivitamin and cocoa extract; daily multivitamin and placebo; daily cocoa extract and placebo; or placebo-only.



Measures: Five epigenetic clocks used as DNA markers that act like “aging clocks,” showing how fast or slow someone’s body is aging at a cellular level on the inside.



“These findings add to a growing body of evidence around multivitamin use and healthy aging,” said Alpa V. Shah, Senior Director, Medical & Scientific Affairs, Haleon. “This COSMOS ancillary study provides new insight into how a daily multivitamin like Centrum Silver may relate to biological aging measures, complementing existing research on cognition and overall nutritional support.”


A Haleon brand, Centrum has been a long-time champion of nutrition research, a commitment that has made Centrum the most clinically studied multivitamin brand in the world. Backed by over 40 years of nutritional science, Centrum delivered on this legacy by providing Centrum Silver product, placebo, and packaging for the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) trials and continues to support other nutrition and multivitamin research. This research reinforces the credibility, efficacy and scientific rigor that underpins Haleon’s portfolio of trusted, science-backed brands.


About Centrum

Centrum has spent decades listening to the human body and learning what it needs to thrive. As the most clinically studied multivitamin brand in the world, Centrum continues its long-standing commitment to advancing nutritional science and supporting healthy aging. For more information about Centrum and Centrum Silver, visit Centrum.com.


About Haleon US

Haleon (NYSE: HLN) is a leading global consumer health company with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans six major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, Wellness, and Sexual Wellness. Built on trusted science, innovation, and deep human understanding, Haleon’s U.S. brands include Abreva, Advil, Benefiber, Centrum, Emergen-C, Eroxon, Excedrin, Flonase, Gas-X, Nexium, Nicorette, Parodontax, Polident, Preparation H, Pronamel, Sensodyne, Robitussin, Theraflu, TUMS, Voltaren, and more. For more information on Haleon and its brands, please visit www.haleon.com or contact USMediaRelations@haleon.com.


Frequently Asked Questions (FAQ)

What is biological aging, and why does it matter?



Biological aging reflects how well the body is functioning, which can differ from chronological age.



It can be measured with biomarkers such as DNA methylation–based epigenetic clocks, which are an evolving scientific tool.



What is Centrum Silver?



Centrum Silver is a daily multivitamin formulated for adults 50+ and is the most clinically studied multivitamin brand in the world, having been included in, among other trials, in the main COSMOS trial and multiple ancillary analyses of the COSMOS trial.



What did this COSMOS ancillary study find?



Compared to the placebo-only group, people in the multivitamin group had slowing in all five epigenetic clocks, including statistically significant slowing seen in the two clocks that are predictive of mortality. Study authors state that the changes equated to about four months less biological aging over the course of two years. Additionally, people who were biologically older than their actual age at the start of the trial benefited more.



In the COSMOS trial, participants were randomized to receive a daily multivitamin, cocoa extract, both interventions, or placebo. The slowing in biological aging observed in this ancillary analysis was seen in the multivitamin group compared to placebo. The findings reported in this analysis are specific to the multivitamin intervention.



Can Centrum Silver help slow biological aging?



Yes. The results from this new analysis suggest that Centrum Silver may slow biological aging.



What are epigenetic clocks?



Epigenetic clocks are biomarkers based on DNA methylation patterns that estimate biological aging. They are an emerging tool and not a diagnostic measure.



Who conducted the research?



The ancillary study was led by independent academic researchers at Mass General Brigham and Augusta University as part of the broader COSMOS program.



Was Centrum involved in the study?



Yes. These independent academic researchers used Centrum Silver as the daily multivitamin tested in the ancillary study.



Where can I read the study?



The full Nature Medicine study can be found at https://www.nature.com/articles/s41591-026-04239-3.



These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309182881/en/
MEDIA CONTACT

Ellie Carone

Ellie.Carone@edelman.com


Original: Study in Nature Medicine Finds Taking Centrum Silver Daily May Slow Biological Aging

PFE hasn’t yet started monetization of HLN stake (as of the 5/11/23 filing date), but this should start fairly soon:

https://www.sec.gov/Archives/edgar/data/1900304/000162828023018229/sch13d-a2_hal.htm

PFE has a 32% stake in HLN, worth ~$12.7B at the current market price.